Clinical Scorecard: Urine as a Cancer ‘Biopsy’?

At a Glance

Key Highlights

• Tumor-derived EVs can be detected in urine, providing a noninvasive cancer testing method.
• The kidney glomerulus actively internalizes and transports circulating EVs into urine.
• Urinary EVs may reflect systemic tumor signals from cancers outside the urinary tract.
• The study utilized engineered cancer cell types to track EV movement in vivo.
• Findings suggest that glomerular processing may enrich certain EV populations in urine.

Guideline-Based Recommendations

Diagnosis

• Utilize urine-based assays to detect tumor-derived EVs as potential biomarkers.

Management

• Further research is needed to validate the clinical utility of urinary EVs in cancer diagnostics.

Monitoring & Follow-up

• Assess the stability and diagnostic value of tumor-derived biomarkers in urine.

Risks

• Further studies are required to evaluate the mechanism's applicability across different tumor types.

Patient & Prescribing Data

Individuals diagnosed with or suspected of having cancer.

Urine-based liquid biopsy approaches may offer a less invasive alternative for monitoring cancer.

Clinical Best Practices

• Incorporate urine-based tests for cancer detection in clinical practice as they become validated.
• Monitor the composition of urinary EVs to enhance biomarker discovery.

References

• Science Advances